Health
ALS access law reauthorized through fiscal year 2031Extend the ALS research runway
The signed reauthorization belongs in the completed-legislation column. Program delivery and medical results have retained separate owners.
- Executive owner
- Donald J. Trump / Health and Human Services / Program Administration
- Status
- ALS access law reauthorized through fiscal year 2031
- Due
- Program authorization through fiscal year 2031
- Paying for it
- Federal program funding subject to applicable appropriations; signing notice gives no expenditure total
ACTIVITY
UpdatedThe authorization end date has been updated to fiscal year 2031.
I signed it. Keep the work moving.
Authorization and expenditure tracking remain separate.
Everything has a different tracking, I sign one bill and suddenly three people arrive with three spreadsheets. Very organized people, sometimes TOO organized to tell me what happened. Give me the progress on one page, the actual progress, not a photograph of the spreadsheets.
I want results people can use.
Updates will identify delivered work and the evidence supporting each result.
Good. I can sign the extension goodly, very goodly, but the researchers have to do the researching. Put their work at the top of the report.
PUBLIC RECORD
The White House announced that Trump signed H.R. 8205, the Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026, on November 3. It reauthorizes the existing act through fiscal year 2031. The signing announcement establishes the legislative extension; it does not announce a new approved therapy, a cure, or a completed funding disbursement.